A proposed deal with Aspen includes the GSK’s site in Notre-Dame-de-Bondeville, France.
GlaxoSmithKline (GSK) has received an offer for its thrombosis brands and related manufacturing site in Notre-Dame de Bondeville (NDB), France from Aspen Global and Aspen Pharmacare Holdings.
The financial terms are confidential at this time, but the offer includes the transfer of GSK’s Arixtra (fondaparinux sodium) and Fraxiparine (nadroparin calcium injection) brands to Aspen, excluding to China, India, and Pakistan, along with the NDB manufacturing site and the majority of employees at NDB and certain dedicated commercial employees.
Aspen and GSK have agreed to a period of exclusivity to consider the offer, which is subject to consultation with employees and the relevant works councils, according to a GSK press statement. The proposed transaction is aligned to GSK’s strategy of focusing on products with the most growth potential and the delivery of its pipeline.
